GlassScriptPhysician profile
Sameer P Desai
NPI 1487776373
$26,749.88
in general payments reported to CMS, 2019-2025
59 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,320 · 2020: $495 · 2021: $2,817 · 2022: $2,960 · 2023: $9,435 · 2024: $5,371 · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,993 · Honoraria: $5,500 · Food and Beverage: $3,052 · Travel and Lodging: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,992.50 |
| Honoraria | $5,500.00 |
| Food and Beverage | $3,051.79 |
| Travel and Lodging | $613.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $9,722.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,965.53 | 2019-2025 | Tagrisso, Calquence, Enhertu |
| Daiichi Sankyo INC. | $2,669.35 | 2021-2024 | Enhertu |
| Beigene USA, INC. | $1,925.00 | 2024 | Brukinsa |
| Glaxosmithkline, LLC. | $1,830.85 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $1,704.41 | 2019-2025 | |
| Stemline Therapeutics INC. | $1,184.26 | 2023-2024 | Orserdu |
| Taiho Oncology, INC. | $1,130.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $403.58 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $225.01 | 2020-2025 | Talvey |
| Celgene Corporation | $215.94 | 2019-2025 | Reblozyl |
| Astellas Pharma US INC | $168.44 | 2019-2025 | Padcev, Xtandi, Xospata |
| Blueprint Medicines Corporation | $158.18 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $142.48 | 2021-2025 | |
| Amgen INC. | $140.50 | 2019-2023 | Blincyto, Kyprolis |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $137.44 | 2020-2023 | Xpovio |
| Covidien LP | $137.20 | 2019 | |
| Pfizer INC. | $109.10 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $104.92 | 2022-2024 | Clonoseq |
| Comsort, INC | $100.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $90.06 | 2020-2025 | Onivyde, Somatuline Depot |
| Aveo Pharmaceuticals, INC. | $89.88 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $81.45 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $76.43 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $75.71 | 2024 | Keytruda, Lynparza, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $69.95 | 2020 | |
| Gilead Sciences, INC. | $66.66 | 2021-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $63.90 | 2022-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $63.30 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $57.48 | 2023-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $54.70 | 2023-2024 | Columvi, Polivy, Lunsumio |
| Jazz Pharmaceuticals INC. | $54.11 | 2024-2025 | |
| Mirati Therapeutics, INC. | $52.77 | 2023-2024 | Krazati |
| Novocure INC. | $50.29 | 2019-2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $45.10 | 2019-2025 | Venclexta |
| Exelixis INC. | $37.42 | 2024-2025 | Cabometyx |
| Telix Pharmaceuticals | $36.95 | 2025 | Illuccix |
| Incyte Corporation | $36.19 | 2024-2025 | Jakafi |
| Eisai INC. | $34.56 | 2025 | |
| Azurity Pharmaceuticals, INC. | $34.38 | 2024-2025 | Vivimusta, Danziten |
| Seagen INC. | $34.34 | 2023 | Tukysa, Padcev |
| Pharmaessentia USA Corporation | $33.90 | 2025 | Besremi |
| Puma Biotechnology, INC. | $33.54 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.45 | 2019-2024 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $28.28 | 2023 | Ultomiris |
| Emmaus Medical, INC. | $26.11 | 2023 | Endari |
| Sirtex Medical INC | $21.68 | 2019 | |
| Adc Therapeutics America, INC. | $21.18 | 2023 | |
| Apellis Pharmaceuticals, INC. | $19.77 | 2024 | Empaveli |
| Array Biopharma INC | $18.97 | 2024 | Tukysa, Braftovi, Mektovi |
| Emd Serono, INC. | $18.05 | 2023 | Bavencio |
| Sobi, INC | $15.96 | 2024 | |
| Deciphera Pharmaceuticals INC. | $15.95 | 2025 | Tgct, Qinlock |
| Spectrum Pharmaceuticals INC. | $15.70 | 2023 | Rolvedon |
| Octapharma USA, INC. | $15.67 | 2024 | Panzyga |
| Verastem, INC. | $15.44 | 2020 | |
| Beone Medicines USA, INC. | $14.82 | 2025 | Brukinsa |
| Alnylam Pharmaceuticals INC. | $14.32 | 2024 | Givlaari |
| Foundation Medicine, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.